NOVARTIS AG (NVS) is held by 11 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 4 funds adding and 6 funds trimming or exiting versus the previous quarter. 0 members of Congress reported 0 purchases vs 1 sale. Latest close $155.21 as of Nov 18, 2026.
Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: none in the last 90 days · Congress to Nov 16, 2026.
Bristol (John W. Bristol & Co.) · Harding Loevner · Tweedy Browne — 11 tracked funds hold NVS. See all holders.
0 members of Congress reported buying (0 purchases vs 1 sale). Politician trading
MANULIFE FINANCIAL CORP (MFC) · NATIONAL GRID PLC (NGG) · BANCO SANTANDER SA-SPON ADR (SAN) · TELKOM INDONESIA PERSERO-ADR (TLK) · Infosys Ltd (INFY) — stocks the same funds also hold. See all related stocks.
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| Bristol (John W. Bristol & Co.) | 1.29% | 557,777 | TRIMMED (-0.7%) Q3 filed Nov 13 |
| Harding Loevner | 0.85% | 578,234 | TRIMMED (-1.0%) Q3 filed Nov 16 |
| Tweedy Browne | 0.84% | 71,125 | TRIMMED (-0.3%) Q3 filed Nov 4 |
| GQG Partners | 0.63% | 2,151,131 | TRIMMED (-12.1%) Q3 filed Nov 13 |
| Saturna Capital | 0.60% | 311,392 | ADDED (+0.1%) Q3 filed Nov 16 |
| Kahn Brothers Group | 0.33% | 13,186 | TRIMMED (-1.5%) Q3 filed Nov 16 |
| Dodge & Cox Funds | 0.06% | 759,373 | TRIMMED (-89.1%) Q3 filed Nov 13 |
| Maverick Capital | 0.04% | 27,789 | ADDED (+82.3%) Q3 filed Nov 16 |
| Thornburg Investment Management | 0.01% | 4,114 | HELD Q3 filed Nov 13 |
| Mondrian Investment Partners | 0.01% | 3,273 | ADDED (+39.1%) Q3 filed Oct 23 |
| Causeway Capital Management | <0.01% | 1,501 | ADDED (+0.9%) Q3 filed Nov 13 |
Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.
Price change since quarter-end: +3.2% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.
Tracked funds holding this stock, by quarter (2017Q2–2017Q4, 3 quarters). Source: quarterly BEST lists from 13F filings — tracked funds only, not all filers. A stock appears here only if it ever made a quarterly BEST list.
| Institutions holding | 1,630 of 8,857 filers |
| Long-only filers among them | 1,618 |
| Change vs 2026 Q1 | +42 net · 1,329 entered · 1,287 exited |
| Shares reported, all filers | 135,353,085 |
| Reported value, all filers | $21.5B |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | NYSE |
| Industry | Pharmaceutical Preparations (SIC 2834) |
| Net income · FY2025 | $14.0B |
| Total assets · FY2025 | $110.9B |
| Shares outstanding | 1,908,151,679 |
| Market cap (at latest close) | $296.2B |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Dec 31, 2025.
| Shares short · Oct 15, 2026 | 5,585,310 |
| Share of shares outstanding | 0.29% |
| Days to cover | 3.20 |
Shares short at recent settlements — Jul 31, 2026: 5.2M · Aug 14, 2026: 5.0M · Aug 31, 2026: 5.6M · Sep 15, 2026: 5.2M · Sep 30, 2026: 5.6M · Oct 15, 2026: 5.6M.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Dec 31, 2025.
| Shares failed to deliver · Oct 14, 2026 | 50 |
| Share of shares outstanding | 0.00% |
| Fails as a share of short interest · Oct 15, 2026 | <0.1% |
Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 15K · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 50.
Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Dec 31, 2025.
Data unavailable — no Form 4 transactions for this ticker were parsed in the last 90 days.
| Filed | Seller | Role | Shares to sell | Market value | Approx. sale date | Source |
|---|---|---|---|---|---|---|
| Apr 30, 2026 | Bulto Carulla Victor | Officer | 6,800 | $1.0M | Apr 30, 2026 | SEC filing |
| Feb 12, 2026 | Marshall Fiona | Officer | 30,743 | $5.0M | Feb 12, 2026 | SEC filing |
| Feb 9, 2026 | Bulto Carulla Victor | Officer | 7,500 | $1.2M | Feb 9, 2026 | SEC filing |
| May 23, 2025 | Marshall Fiona | Officer | 15,000 | $1.7M | May 23, 2025 | SEC filing |
| Apr 30, 2025 | Kowalski Robert William | Officer | 1,212 | $137.3K | Apr 30, 2025 | SEC filing |
| Aug 12, 2024 | Kowalski Robert William | Officer | 6,566 | $733.6K | Aug 12, 2024 | SEC filing |
| May 22, 2024 | Gal Aharon | Officer | 2,500 | $254.8K | May 22, 2024 | SEC filing |
| Sep 19, 2023 | Kowalski Robert William | Officer | 1,581 | $162.7K | Sep 19, 2023 | SEC filing |
A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.
| Filed | Filer | Form | Shares | % owned | Event date | Source |
|---|---|---|---|---|---|---|
| Jul 17, 2025 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | SC 13G | 139,602,467 | 6.4% | Sep 30, 2024 | SEC filing |
One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.
0 members of Congress reported buying (0 purchases vs 1 sale).
Source: U.S. House Clerk and U.S. Senate eFD STOCK Act periodic transaction reports, as of Nov 16, 2026. Reported amounts are ranges, and reports can arrive up to 45 days after the trade.
Recent activity by member
| Member | Chamber | Party | Buys | Sells | Latest | Amount range |
|---|---|---|---|---|---|---|
| Hern, Kevin | House | R | 0 | 1 | Aug 27, 2026 | $15,001 - $50,000 |
Member-level activity in the current window, most recent first (House data to Nov 16, 2026, Senate to Oct 1, 2026). House reports arrive as PDFs without transaction-level rows in the current corpus, so this table shows per-member totals, not individual trades; the member page lists the underlying filings. Senate rows link the same way — the member page carries the eFD filing links.
Industry: Pharmaceutical Preparations (SIC 2834). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.
None of the members who traded this stock in the current window sit on these committees.
Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.
Lobbying: 5 Lobbying Disclosure Act filings named this company as client, 2002–2006; most common issues: Health Issues (2), Budget/Appropriations (1), Agriculture (1).
Federal contracts: $50.1M in obligated amounts, fiscal years 2021–2026.
| Fiscal year | Obligated amount |
|---|---|
| FY2021 | $7.9M |
| FY2022 | $15.2M |
| FY2023 | $2.9M |
| FY2024 | $24.2M |
| FY2025 | $-80.0K |
| FY2026 | $0 |
Largest awards collected
| Award ID | Agency | Amount | Start |
|---|---|---|---|
| HHSD200201561394C | Department of Health and Human Services | $477.4K | Feb 6, 2015 |
| 36C24921N0367 | Department of Veterans Affairs | $283.6K | Mar 8, 2021 |
| 36C24921N0323 | Department of Veterans Affairs | $283.6K | Jan 26, 2021 |
| 36C24921N0300 | Department of Veterans Affairs | $283.6K | Jan 12, 2021 |
| 36C25721N0069 | Department of Veterans Affairs | $283.5K | Oct 16, 2020 |
Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.
Chart Signals
· Monthly Uptrend — Price above its 12-month moving average
Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.
· Super-investor 13F BEST — appeared in 3 of the last 40 quarterly lists; latest 2017 Q4, ranked #34 of 50.
| 13F signal (2021 Q3 – 2026 Q1) | Events | Win rate | Avg return | SPY | Excess |
|---|---|---|---|---|---|
| Heavy accumulation — 3+ tracked funds increased together | 3 | 33.3% | -1.8% | -2.9% | +1.2% |
Measured from SEC 13F filings: entry at the close on the first trading day after each quarter’s filing deadline, exit one quarter later on the same rule, dividend-adjusted closes. Past records do not guarantee future results — see Track Record and Methodology.
Also held by the tracked funds that hold NVS — ranked by lift, the co-holding pattern described in Methodology: MANULIFE FINANCIAL CORP (MFC) · NATIONAL GRID PLC (NGG) · BANCO SANTANDER SA-SPON ADR (SAN) · TELKOM INDONESIA PERSERO-ADR (TLK) · Infosys Ltd (INFY) · Sanofi (SNY) · NOVO NORDISK A S (NVO) · ALLSTATE CORP (ALL).
No Form 8-K filings for this ticker in the index (Jan 2023 – present).
MANULIFE FINANCIAL CORP (MFC) · Track Record: how the signals scored · Practice timing on NVS
One email a week: the week’s new filings and research. Subscribe free
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.